Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-01

Study Completion Date

2024-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Glycosuria on Urinary Protein in Patients With Chronic Kidney Disease Treated With SGLT2 Inhibitors

NCT07084038

Chronic Kidney Disease

ACTIVE_NOT_RECRUITING

Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes

NCT06532682

Diabetic Kidney Disease Type 1 Diabetes

ACTIVE_NOT_RECRUITING PHASE4

Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension

NCT00407680

Type 2 Diabetes Mellitus Hypertension

UNKNOWN PHASE4

A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

NCT06651021

Healthy Volunteer

COMPLETED PHASE1

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

NCT04127084

Type 2 Diabetes Diabetic Nephropathy

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project is a single-center retrospective cohort study to obtain the biochemical index levels of urinary albumin creatinine ratio, urinary protein creatinine ratio, blood renal function, blood lipids, and blood glucose at the immediate, 3rd, 6th, and 12th month of cohort inclusion in each group of patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Antidiabetic Drugs

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SGLT2i+ARNI

patients in this group received SGLT2i combined with ARNI medication。

No interventions assigned to this group

SGLT2i only

patients in this group received SGLT2i medication only。

No interventions assigned to this group

ARNI only

patients in this group received ARNI medication only。

No interventions assigned to this group

control

patients in this group received neither SGLT2i nor ARNI。

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than or equal to 18 years
* Clinical diagnosis of type 2 diabetes mellitus
* Immediate urine albumin creatinine ratio greater than 30mg/g
* Signed informed consent and available for follow-up

Exclusion Criteria

* severe renal insufficiency, i.e. eGFR ≤ 30ml/min/1.75m2
* clinical diagnosis of various acute and chronic urinary tract infections
* combined with various serious infectious diseases
* combined with acute complications of diabetes mellitus
* end-stage malignancy
* pregnancy and lactation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No